Related Experiment Video
Updated: Jun 27, 2025
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
20.4K
Is the Risk of Intrahepatic Cholestasis Increased with Supplemental Progesterone?
Matthew C H Rohn1, Lindsey Vignali1, Isabel Reeder2
1Department of Obstetrics and Gynecology, George Washington University Hospital, Washington, District of Columbia.
American Journal of Perinatology
|May 7, 2024
Summary
This study found no link between supplemental progesterone and intrahepatic cholestasis of pregnancy (ICP). Previous research shows mixed results, possibly due to different progesterone formulations or administration routes.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pharmacology in Pregnancy
Background:
- Intrahepatic cholestasis of pregnancy (ICP) is a serious pregnancy complication.
- The role of supplemental progesterone in ICP development is debated.
- Recent evidence suggests a potential link, necessitating further investigation.
Purpose of the Study:
- To evaluate the association between supplemental progesterone use during pregnancy and the incidence of intrahepatic cholestasis of pregnancy (ICP).
Main Methods:
- A retrospective, matched case-control study was conducted from 2012-2022.
- 120 ICP cases were matched with 360 controls.
- Logistic regression adjusted for ART use and liver disease history.
Main Results:
- Cases had higher rates of liver disease history, multiple gestations, prior ICP, and earlier delivery.
- No significant difference in supplemental progesterone use was observed between ICP cases and controls.
- Unadjusted and adjusted analyses showed no association (aOR=0.98, 95% CI: 0.24-3.94).
Conclusions:
- This study did not find an association between supplemental progesterone and ICP.
- The risk may depend on progesterone formulation or route of administration.
- Further research is needed to clarify the progesterone-ICP relationship.
More Related Videos
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:27Ovarian Cycle
1.2K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.2K
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
414
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
414
01:17Chronic Bowel Disorders: Introduction
445
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
445
01:30Acute Pancreatitis II: Clinical Manifestations and Management
122
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
122